| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
23,343 |
14,691 |
$1.14M |
| U0005 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 |
19,447 |
12,217 |
$291K |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
13,753 |
5,972 |
$282K |
| 87798 |
Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism |
16,468 |
4,093 |
$267K |
| G2023 |
Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source |
3,620 |
2,683 |
$41K |
| 87481 |
|
4,979 |
3,566 |
$40K |
| 87631 |
|
1,021 |
766 |
$16K |
| 87529 |
|
1,581 |
1,234 |
$12K |
| 87491 |
Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe |
1,608 |
1,307 |
$8K |
| 87661 |
Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe |
1,421 |
1,171 |
$8K |
| 87591 |
Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe |
1,538 |
1,259 |
$8K |
| 87641 |
|
4,072 |
3,205 |
$8K |
| 87651 |
Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe |
3,784 |
2,981 |
$7K |
| 87653 |
|
3,054 |
2,467 |
$7K |
| 87563 |
|
1,531 |
1,255 |
$7K |
| 87640 |
|
3,355 |
2,603 |
$6K |
| 87500 |
|
3,017 |
2,417 |
$5K |
| 87624 |
Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types |
757 |
604 |
$4K |
| 87511 |
|
791 |
648 |
$3K |
| 87581 |
|
1,138 |
877 |
$3K |
| 87551 |
|
241 |
219 |
$1K |
| 87541 |
|
207 |
190 |
$709.14 |
| 87556 |
|
173 |
150 |
$707.90 |
| G0476 |
Infectious agent detection by nucleic acid (dna or rna); human papillomavirus (hpv), high-risk types (e.g., 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68) for cervical cancer screening, must be performed in addition to pap test |
489 |
432 |
$274.12 |
| 81001 |
|
240 |
204 |
$62.42 |
| 87561 |
|
14 |
13 |
$56.14 |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
23 |
12 |
$51.33 |
| 87625 |
|
33 |
31 |
$40.05 |
| 87634 |
|
82 |
77 |
$0.00 |
| 87502 |
Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets |
82 |
77 |
$0.00 |
| 81225 |
|
31 |
31 |
$0.00 |
| K1034 |
Provision of covid-19 test, nonprescription self-administered and self-collected use, fda approved, authorized or cleared, one test count |
198 |
189 |
$0.00 |
| 87486 |
|
124 |
117 |
$0.00 |
| 81226 |
|
31 |
31 |
$0.00 |
| 87637 |
Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV |
20 |
19 |
$0.00 |
| 87498 |
|
20 |
19 |
$0.00 |
| 87496 |
|
20 |
19 |
$0.00 |
| 87532 |
|
22 |
20 |
$0.00 |